TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has made a strategic investment in biotechnology company Junevity and signed a separate licensing agreement covering cosmetic applications. The companies plan to use Junevity’s RESET Platform to identify skin-ageing pathways that could inform cosmetics; no products, launch dates or investment terms have been disclosed.
Amorepacific Ventures, the corporate investment arm of the South Korean beauty company behind Laneige, has invested in biotechnology firm Junevity and signed a separate licensing agreement for cosmetic applications. The companies will use Junevity’s RESET Platform to investigate biological pathways associated with skin ageing, with the aim of informing future skin-care products.
The collaboration combines Junevity’s target-discovery platform with Amorepacific’s expertise in skin biology, cosmetic development and commercialisation. The companies said their research will seek pathways that may be suitable for cosmetic use, including approaches intended to reset skin gene networks toward a healthier state. These are research aims, not evidence that a product or cosmetic effect has already been established.
Under the arrangement, Amorepacific will lead product development and commercialisation for cosmetics arising from the work. Junevity will continue developing therapeutic applications of its platform separately. The investment and licensing agreement are distinct elements of the partnership, but the companies did not disclose the investment amount, licence terms or whether the agreement is exclusive.
Amorepacific R&I Center chief technology officer Brian Byung-Fhy Suh said the work would focus on skin-ageing biology, including gene networks and transcriptional regulation. Junevity co-founder and CEO John Hoekman described skin care as a new market for the platform and said the company’s therapeutic pipeline would continue alongside the collaboration.
Biology Research Meets Cosmetic Development
The deal connects a biotechnology company’s search for biological targets with a major beauty company’s capacity to develop and sell consumer products. If the research identifies pathways that can be translated into safe, substantiated cosmetic applications, it could shape how future products are formulated and how their intended benefits are described. At this stage, however, the partnership is a research and development effort, not a product announcement.
For Amorepacific, the investment gives it a route to explore skin longevity research through a specialist platform while retaining responsibility for cosmetic development and commercialisation. For Junevity, the licensing arrangement creates a route into beauty applications beyond its therapeutic work. The commercial value will depend on research outcomes, product feasibility and the evidence supporting any eventual claims.
As an affiliate, we earn on qualifying purchases.
A Separate Track From Therapeutics
Junevity’s RESET Platform is described by the companies as a system for discovering biological targets and pathways. In this collaboration, its stated application is research into skin ageing and gene networks, rather than the treatment of a medical condition. Cosmetics developed from the work would be subject to the relevant product and claims requirements in the markets where they are sold.
Hoekman also referenced Junevity’s therapeutic pipeline, including a lead siRNA candidate for obesity that he said was headed into human clinical trials. That programme is separate from the Amorepacific agreement: the source report does not say the beauty partnership covers the candidate, or that the skin-care research is itself a clinical programme. Keeping the two tracks distinct is important when interpreting the company’s comments about the breadth of its technology.
“The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.”
— Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center
As an affiliate, we earn on qualifying purchases.
Investment Terms and Products Undisclosed
The companies have not disclosed the investment amount, financial terms of the licence, research schedule or any milestones for deciding whether a candidate pathway can be used in a cosmetic. The source report also gives no product names, ingredient details, launch markets or expected release dates.
It remains unclear which specific pathways the RESET Platform may identify, how the companies will assess possible cosmetic effects, and what evidence would support consumer-facing claims. The description of products intended to reset or rejuvenate skin gene networks reflects the collaboration’s goal; it should not be read as a demonstrated effect or as confirmation that a product is in development for launch.
cosmetics with gene network reset technology
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Research Before Any Product Launch
The immediate next step is the joint research described by the companies: Junevity will apply its target-discovery platform to skin-ageing questions alongside Amorepacific’s skin biology expertise. If the work yields candidates suitable for cosmetics, Amorepacific is expected to lead their development and commercialisation under the arrangement.
No public timetable or next milestone has been provided. Further details to watch for include named research targets, evidence from development work, product or ingredient announcements, and disclosures about how any cosmetic benefits will be tested and substantiated. Until then, the confirmed development is the investment and research partnership, rather than a finished or scheduled product.
As an affiliate, we earn on qualifying purchases.
Key Questions
What has Amorepacific announced?
Amorepacific Ventures invested in Junevity and the companies signed a separate licensing agreement for cosmetic applications. They plan joint research into skin-ageing pathways using Junevity’s RESET Platform.
What is Junevity’s RESET Platform intended to do in this partnership?
The companies say it will be used to discover biological targets and pathways related to skin ageing. The source does not provide technical results or identify a specific pathway found through the collaboration.
Are new products or launch dates confirmed?
No. The companies have not announced a product, ingredient, launch date or development timetable. Amorepacific is expected to lead cosmetic development and commercialisation if the research supports products.
Is the collaboration a clinical treatment programme?
The announced partnership concerns cosmetic applications. Junevity’s therapeutic research, including the obesity candidate mentioned by its CEO, is described separately and is not presented as part of the skin-care agreement.
What financial terms were disclosed?
The investment amount and the financial and licensing terms were not disclosed in the source report.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
